- The U.S. Department of Justice notifies Abiomed (NASDAQ:ABMD) that its investigation into its marketing practices of Impella 2.5 has been closed with no enforcement action planned.
- On October 26, 2012 the U.S. Attorney's Office for the District of Columbia initiated an inquiry and requested documents related to its marketing of the product and its labeling.
- The Impella 2.5 is a ventricular assist device that is used during high risk percutaneous coronary interventions.